Industry News Archives | International Rett Syndrome Foundation

March 5, 2025

Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med

Filter

Acadia

Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med

Taysha

Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update

Acadia

Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome

Neurogene

Update on Patient SAE & Discontinuation of High Dose Protocol (Community Letter)

Neurogene

Update on Patient SAE (Community Letter)

Neurogene

Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

Taysha

Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Neurogene

Neurogene Community Letter

Neurogene

Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome